Selective in vivo expansion of tumor-specific T cells enabling persistent and strong anti-tumor responses

Our Novel Combination Approach Delivers Superior Cell Therapy Outcomes:

• Enhanced Efficacy – Selective in vivo expansion, activation and persistence of tumor-specific T cells
• Improved Safety – Eliminates systemic IL-2 dosing and its associated toxicities
• Simplified Treatment – Limits the need for patient lymphodepletion preconditioning
• Lower Costs, Faster Delivery – Enables reduced T cell therapy doses, lower costs and shorter vein-to-vein times
• Broad Scalability – Addresses broad patient needs across multiple cancer indications
• Simple Engineering – Naturally occurring T cell receptors with clinically validated off the shelf biologics booster

Our Transformative Approach

• Starting with a very low T cell therapy dose
• Expanding and sustaining tumor-specific T cells
• Clinically validated and safe T cell booster
• No complex cell engineering and manipulation

Selecting the Best Naturally Occurring T Cell Receptors

Our Deep Immunomics platform enables discovery and selection of natural occurring TCRs with high potency and no cross-reactivity.

Precise Activation and Expansion of Tumor-Specific T Cells

Mimicking the Natural Immune Synapse

• Selective binding by T cells expressing the cognate TCR
• Two-signal activation mediated through the specific TCR and the costimulatory domain
• Exclusive activation and expansion of tumor-epitope specific T cells

A Modular Platform Accelerating the Development of Novel Therapies

Some images created with Biorender